Transforming Care for People with MASH
Our therapeutic approach directly targets the underlying causes of metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease.
Kerry, patient advocate
The Science Driving Our Approach
Madrigal’s pioneering scientific advances in MASH are rooted in more than a decade of research establishing the central role of the thyroid hormone receptor-beta (THR-β) pathway in liver health.
In people with MASH, the liver’s ability to regulate key metabolic processes breaks down, leading to problems like inflammation, fat (lipid) buildup and reduced energy production (mitochondrial dysfunction). These issues damage liver cells, causing scarring (fibrosis) that can worsen over time. The foundation of our scientific platform is to directly target THR-β in the liver.
Anchored in this approach, Madrigal is expanding and strengthening its MASH pipeline to address multiple drivers of disease. We believe the next wave of innovation in MASH will be defined by combination strategies to help address the full spectrum of patient needs.
“We are not just advancing a pipeline. We’re laying the
foundation to transform how MASH is treated.”– David Soergel, M.D.
Chief Medical Officer
Understanding MASH
Explore what MASH is, how it progresses and why early identification matters. You’ll also find resources for people impacted by MASH, including patient stories and disease education.
References
Harrison SA, Bedossa P, Guy CD, et al; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497-509.
Karim G, Bansal MB. Resmetirom: an orally administered, small molecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. touchREV Endocrinol. 2023;19(1):60-70.
Madrigal press release. Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs; 2026.